Pyxis Oncology, Inc.
PYXS · XNASCIK 1782223fmd_0R96J2VY17B5K8RDJWM7PYKD39Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 16 | 14 |
| Cost of revenue | – | – | – | – | 0 | 2 |
| Gross profit | – | – | – | – | 16 | 11 |
| Research and development | 9 | 51 | 86 | 50 | 59 | 74 |
| Total operating expenses | 13 | 70 | 123 | 82 | – | – |
| Operating income | (13) | (70) | (123) | (82) | (89) | (84) |
| Interest and investment income | 0 | 0 | 3 | 2 | 1 | 1 |
| Other non-operating income (expense) | 0 | (6) | 3 | 8 | 10 | 6 |
| Income before taxes | – | – | – | (74) | (79) | (78) |
| Income tax expense | – | – | – | – | (2) | 1 |
| Net income from continuing operations | – | – | – | – | (77) | (80) |
| Net income | (13) | (76) | (121) | (74) | (77) | (80) |